Monograph Details
|
|
Neoplasms
> Topoisomerase inhibitors
|
|
VEPESID |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Topoisomerase inhibitor. |
| Generic Name |
|
Etoposide 50mg; caps; contain parabens. |
| Indications |
|
Small cell lung cancer. |
| Children |
|
Not recommended. |
| Adults |
|
Round dose to nearest 50mg increment. Range: 70mg/m2 per day for 4 days to 100mg/m2 per day for 5 days. Repeat course every 3 to 4 weeks after recovery (esp myelosuppression). Renal impairment (CrCl ≤50mL/min): reduce dose (see literature). Consider dose reduction with existing myelosuppression due to previous radiation or chemotherapy. |
| Precautions |
|
Monitor blood (esp CBC/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Pregnancy (Cat.D); nursing mothers: not recommended. |
| Interactions |
|
Potentiated by cyclosporine. Additive toxicity with radiation, other cytotoxic therapies. |
| Adverse Reactions |
|
GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), alopecia, fever, infections, peripheral neurotoxicity; hypersensitivity reactions, acute leukemia (rare); others. |
| How Supplied |
|
Caps—20 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
